Dateline City:
KENILWORTH, N.J.
Samsung Bioepis Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Samsung Bioepis Co., Ltd. has received approval of
RENFLEXIS (infliximab), a biosimilar of the immunology medicine
Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck
will commercialize Samsung Bioepis RENFLEXIS in Korea as part of
Mercks commercialization partnership with Samsung Bioepis to offer
high-quality biosimilar alternatives to existing biologic medicines.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more